Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176813 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00176813: Completed Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
NCT00176813 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00176813, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will examine an investigational (experimental) treatment using gemcitabine, cisplatin, and celecoxib. Preliminary studies have shown that this experimental treatment may be effective in reducing the size of cancerous tumors and/or preventing further tumor growth. This is a phase II clinical trial studying the reactions of the patient's body and their tumor to the combination of gemcitabine, cisplatin, and celecoxib. The purpose of this study is to see if the tumor responds to this treatment and to determine how long the response lasts. This study will also look at what kind of side effects this experimental treatment causes and see how often these side effects occur. Blood levels of celecoxib will be measured to find out how this treatment affects factors (proteins) involved in new blood vessel formation and tumor growth (angiogenesis).
Interventions
- DRUG Cisplatin
- DRUG Celecoxib
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
What the finished NCT00176813 record still lists
NCT00176813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00176813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00176813 about?
NCT00176813 is a clinical study titled "Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer". This study will examine an investigational (experimental) treatment using gemcitabine, cisplatin, and celecoxib. Preliminary studies have shown that this experimental treatment may be effective in reducing the size of cancerous tumors and/or preventing further tumor growth. This is a phase II clini...
What is the current status of trial NCT00176813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2003-03. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00176813?
The interventions under investigation include: Cisplatin (DRUG), Celecoxib (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00176813?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00176813's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia